Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MLLT10
REST API REST API
Homo sapiens
MLLT10 is differentially expressed in 330 experiments: 166 organism parts: testis, bone marrow, ... (164 more);, 229 disease states: normal, breast carcinoma, ... (227 more);, 101 cell types 472 cell lines 55 compound treatments and 81 other conditions.
Synonyms AF10
Orthologs Q4H3X3_CIOIN (Ciona intestinalis)   Mllt10 (Rattus norvegicus)   mllt10 (Danio rerio)   MLLT10 (Gallus gallus)   Mllt10 (Mus musculus)   ENSCING00000017525 (Ciona intestinalis)   NTO1 (Saccharomyces cerevisiae)   MLLT10 (Bos taurus)   Alh (Drosophila melanogaster)   mllt10 (Xenopus laevis)   MLLT10 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, cytoplasm, transcription, DNA-dependent, metal ion binding, positive regulation of transcription from RNA polymerase II promoter, nucleus, zinc ion binding, sequence-specific DNA binding transcription factor activity
InterPro Term Znf_PHD-finger, Znf_PHD
UniProt Accession Q66K63, Q71UR7, P55197, B4DVS6, Q6N002, Q5JU80, Q5JT34, Q5JT35, B1ANA8, Q5VX90, E9PBP4, F5H541
Gene-Disease Assocation LEUKEMIA, ACUTE MYELOID; AML
Search EB-eye ENSG00000078403
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, ... (33 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (41 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823, E-GEOD-3529
AGS
2
E-MTAB-37, E-GEOD-15460
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
HCC2157
2
E-MTAB-37, E-MTAB-62
MCF7
2
E-GEOD-5258, E-MTAB-37
MOLT4
2
E-MTAB-62, E-MTAB-37
466 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, E-GEOD-13909, ... (47 experiments)

Factor Value U/D Experiments
stromal cell
2
E-GEOD-10797, E-MEXP-2034
induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
embryonic stem cell
2
E-GEOD-26672, E-MEXP-930
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
keratinocyte
1
E-GEOD-3204
plasma cell
1
E-MEXP-2360
95 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-TABM-15, ... (69 experiments)

Factor Value U/D Experiments
cervical carcinoma
4
E-MTAB-62, E-MTAB-37, E-MEXP-1331, E-GEOD-5823
control
4
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363, E-GEOD-20602
dermatomyositis
3
E-GEOD-1551, E-GEOD-5370, E-MTAB-62
chronic myelogenous leukemia
3
E-GEOD-5550, E-MTAB-62, E-MTAB-37
gastric carcinoma
2
E-MTAB-37, E-GEOD-15460
Wilms tumor
2
E-MTAB-37, E-GEOD-2712
223 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-697, E-GEOD-3720, E-GEOD-5824, ... (32 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-TABM-868, E-MEXP-1958, E-GEOD-3720
ethanol
2
E-MEXP-2241, E-GEOD-3113
mercaptopurine, methotrexate
1
E-GEOD-412
interferon-gamma + lipopolysaccharide
1
E-GEOD-7307
saline
1
E-GEOD-3026
ponasterone A
1
E-GEOD-3113
49 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
32
2
1
E-GEOD-3494
28
2
1
E-GEOD-3494


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-994, E-MEXP-1251, E-GEOD-21374, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-2509, E-MEXP-2280, E-TABM-147, E-GEOD-21138, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-TABM-868, E-GEOD-18005, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (38 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-GEOD-17400, E-GEOD-6802, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.451 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM